Carcinoma, Non-Small-Cell Lung Clinical Trial
Official title:
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
Verified date | December 2023 |
Source | Seagen Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will test the safety of a drug called SGN-ALPV in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have three parts. Parts A and B of the study will find out how much SGN-ALPV should be given to participants. Part C will use the dose and schedule found in Parts A and B to find out how safe SGN-ALPV is and if it works to treat solid tumor cancers.
Status | Terminated |
Enrollment | 43 |
Est. completion date | December 13, 2023 |
Est. primary completion date | December 13, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants must have one of the following histologically or cytologically confirmed metastatic or unresectable solid tumor types: - Parts A and B - Ovarian cancer - Endometrial cancer - Non-small cell lung cancer (NSCLC) - Gastric cancer, including gastroesophageal junction (GEJ) carcinoma - Cervical cancer - Malignant testicular germ cell tumor (GCT), except for pure teratomas - Malignant ovarian GCT, except for pure teratomas - Malignant extragonadal GCT except for pure teratomas or tumors with primaries arising from CNS - Part C - High-grade serous ovarian cancer (HGSOC): Participants must have HGSOC which has progressed or relapsed within 6 months after previous platinum containing chemotherapy, received 2 to 4 prior anticancer lines of therapy, and at least 1 line of therapy in the platinum-resistant setting. If eligible at least 1 line of therapy must have contained bevacizumab or a biosimilar to bevacizumab. - Endometrial Cancer: Participants must have unresectable locally advance or metastatic endometrial carcinoma and have had at least 1 prior line of therapy. - NSCLC: Participants must have unresectable locally advanced or metastatic NSCLC and have received platinum-based therapy and a PD-(L)1 inhibitor. - Gastric cancer or GEJ carcinoma: Participants must have unresectable locally advanced or metastatic gastric cancer or GEJ carcinoma and have received prior platinum and fluoropyrimidine -based chemotherapy - Participants enrolled in the following study parts should have an appropriate tumor site and agree to a biopsy - Part B dose and schedule optimization cohorts and Part C disease-specific expansion cohorts: pretreatment biopsy, unless clinically infeasible following consultation with the medical monitor. - Part C biology expansion cohort: pretreatment biopsy (required), on-treatment biopsy during Cycle 1 (unless clinically infeasible following consultation with the medical monitor) - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 - Measurable disease per the RECIST v1.1 at baseline Exclusion Criteria: - History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death. - Known active central nervous system metastases. - Previous receipt of an MMAE-containing agent or an agent targeting ALPP or ALPPL2. - Pre-existing neuropathy = Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 |
Country | Name | City | State |
---|---|---|---|
Canada | Ottawa Hospital Cancer Centre | Ottawa | Ontario |
Canada | University Health Network, Princess Margaret Hospital | Toronto | Ontario |
Spain | START Madrid-CIOCC_Hospital HM Sanchinarro | Madrid | Other |
Sweden | Karolinska University Hospital | Stockholm | Other |
United Kingdom | Sarah Cannon Research Institute UK | London | Other |
United Kingdom | The Royal Marsden NHS Foundation Trust (RM) | London | Other |
United States | Virginia Cancer Specialists | Fairfax | Virginia |
United States | Women's Cancer Care | Fresno | California |
United States | START Midwest | Grand Rapids | Michigan |
United States | Yale Cancer Center | New Haven | Connecticut |
United States | Oklahoma University at Stephenson Cancer Center | Oklahoma City | Oklahoma |
United States | Florida Cancer Specialists - Lake Nona | Wellington | Florida |
United States | START Mountain Region | West Valley City | Utah |
Lead Sponsor | Collaborator |
---|---|
Seagen Inc. |
United States, Canada, Spain, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with adverse events (AEs) | Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. | Through 30-37 days after last study treatment, approximately 6 months | |
Primary | Number of participants with laboratory abnormalities | Through 30-37 days after last study treatment, approximately 6 months | ||
Primary | Number of participants with dose-limiting toxicities (DLTs) | Up to 28 days | ||
Primary | Number of participants with DLTs by dose level | Up to 28 days | ||
Secondary | Incidence of antidrug antibodies (ADAs) | Through 30-37 days after last study treatment, approximately 6 months | ||
Secondary | Area under the concentration-time curve (AUC) | PK parameter | Through 14 days after last study treatment, approximately 6 months | |
Secondary | Maximum concentration (Cmax) | PK parameter | Through 14 days after last study treatment, approximately 6 months | |
Secondary | Time to Cmax (Tmax) | PK parameter | Through 14 days after last study treatment, approximately 6 months | |
Secondary | Apparent terminal half-life (t1/2) | PK parameter | Through 14 days after last study treatment, approximately 6 months | |
Secondary | Trough concentration (Ctrough) | PK parameter | Through 14 days after last study treatment, approximately 6 months | |
Secondary | Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) | The proportion of participants with an objective response (OR) per investigator. A participant is determined to have an OR if, based on RECIST v1.1, the subject achieves a complete response (CR) or a partial response (PR) after initiation of treatment and at or prior to the end of treatment (EOT) disease assessment. | Approximately 2 years | |
Secondary | Duration of objective response (DOR) | The time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression (based on radiographic assessments per RECIST v1.1) or death due to any cause. | Approximately 2 years | |
Secondary | Progression-free survival (PFS) | The time from start of study treatment to first documentation of disease progression or death due to any cause | Approximately 2 years | |
Secondary | Overall survival (OS) | The time from start of study treatment to death due to any cause | Approximately 2 years | |
Secondary | CA-125 response rate according to Gynecological Cancer Intergroup (GCIG) criteria (subjects with ovarian cancer only) | The proportion of participants with ovarian cancer who have at least a 50% reduction in CA-125 value from baseline according to GCIG CA-125 criteria | Approximately 2 years | |
Secondary | Combined RECIST/CA-125 overall response rate according to GCIG (subjects with ovarian cancer only) | The proportion of participants with ovarian cancer whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria | Approximately 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |